Advertisement

Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?

  • C. T. Bahadir
  • G. C. Ecemis
  • H. Atmaca
Original Article
  • 49 Downloads

Abstract

Purpose

The aim of this study was to investigate the possible association of insulin-like growth factor-1 (IGF-1) with the pathogenesis of non-functioning adrenocortical adenomas (NFAs).

Methods

This study included 50 female patients (mean age 54 years) with NFAs, 55 patients (mean age 48 years; 20 male, 35 female) with acromegaly and 38 female control subjects (mean age 58 years). Body mass index (BMI) and waist circumference (WC) of the subjects were recorded and blood samples for IGF-1 were taken. Insulin resistance was calculated using the homeostatic model assessment (HOMA) score. Since most of the acromegaly patients had been using medicine that could have effected insulin resistance, HOMA scores were calculated only in patients with NFAs and the controls. Computerized tomography or magnetic resonance imaging was taken of the acromegalics and controls to detect adrenal mass frequency.

Results

The mean age was similar among the groups. As expected, the serum IGF-1 levels were significantly higher in patients with acromegaly than in patients with NFAs and the controls (p < 0.001). Although BMI, WC, and serum IGF-1 levels were significantly higher (p < 0.001) in patients with NFAs, the HOMA scores were similar between patients with NFAs and control groups. Although none of the control subjects had adrenal masses, NFAs were detected in 14 (25%) out of 55 acromegalic patients.

Conclusions

Higher serum IGF-1 levels in patients with NFAs compared to the control group and an increased prevalence of NFAs in acromegaly patients compared to control subjects and the general population suggest an association of IGF-1 with the etiopathogenesis of NFA.

Keywords

Adrenal incidentaloma Non-functioning adrenocortical adenoma IGF-1 Insulin resistance 

Notes

Acknowledgements

We would like to thank Prof. Dr. Ramis Colak and Prof. Dr. Ayşegul Atmaca for contributing their patients to this study, and we are also grateful to Prof. Dr. Murat Danaci and Prof. Dr. Mehmet Selim Nural for the radiologic evaluation of the subjects included in this study.

Funding

The present study was supported by Ondokuz Mayis University Scientific Research Funding (Project Code No: 1904.12.022).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The investigation was conducted according to the principles expressed in the Declaration of Helsinki.

Informed consent

The participants signed informed consent.

References

  1. 1.
    Kapoor A, Morris T, Rebello R (2011) Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 5:241–247.  https://doi.org/10.5489/cuaj.11135 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Barzon L, Sonino N, Fallo F, Palu G, Boscaro M (2003) Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273–285CrossRefPubMedGoogle Scholar
  3. 3.
    Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, Angeli A, Terzolo M (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29:298–302.  https://doi.org/10.1007/BF03344099 CrossRefPubMedGoogle Scholar
  4. 4.
    Peppa M, Boutati E, Koliaki C, Papaefstathiou N, Garoflos E, Economopoulos T, Hadjidakis D, Raptis SA (2010) Insulin resistance and metabolic syndrome in patients with non-functioning adrenal incidentalomas: a cause-effect relationship? Metabolism 59:1435–1441.  https://doi.org/10.1530/EJE-10-0246 CrossRefPubMedGoogle Scholar
  5. 5.
    Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T (2001) The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54:797–804CrossRefGoogle Scholar
  6. 6.
    Bernini G, Moretti A, Iacconi P, Miccoli P, Nami R, Lucani B, Salvetti A (2003) Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 148:213–219CrossRefPubMedGoogle Scholar
  7. 7.
    Mesiano S, Mellon SH, Jaffe RB (1993) Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. J Clin Endocrinol Metab 76:968–976.  https://doi.org/10.1210/jcem.76.4.8473412 PubMedGoogle Scholar
  8. 8.
    Fottner Ch, Hoeflich A, Wolf E, Weber MM (2004) Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 36:397–405.  https://doi.org/10.1055/s-2004-814563 CrossRefPubMedGoogle Scholar
  9. 9.
    Rechler MM, Zapf J, Nissley SP, Froesch ER, Moses AC, Podskalny JM, Schilling EE, Humbel RE (1980) Interaction of insulin-like growth factors I and II and multiplication stimulating activity with receptors and serum protein carriers. Endocrinology 107:1451–1459.  https://doi.org/10.1210/endo-107-5-1451 CrossRefPubMedGoogle Scholar
  10. 10.
    Kasuga M, Van Obberghen E, Nissley SP, Rechler MM (1981) Demonstration of two subtypes of insulin-like growth factor receptors by affinity cross-linking. J Biol Chem 256:5305–5308PubMedGoogle Scholar
  11. 11.
    Penhoat A, Rainey WE, Viard I, Saez JM (1994) Regulation of adrenal cell-differentiated functions by growth factors. Horm Res 42:39–43CrossRefPubMedGoogle Scholar
  12. 12.
    Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998–1003.  https://doi.org/10.1210/jcem.87.3.8277 CrossRefPubMedGoogle Scholar
  13. 13.
    Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, Epaminonda P, Masserini B, Beck-Peccoz P, Orsi E, Ambrosi B, Arosio M (2007) Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30:83–88.  https://doi.org/10.2337/dc06-1267 CrossRefPubMedGoogle Scholar
  14. 14.
    Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202.  https://doi.org/10.1172/JCI39375 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pappa T, Papanastasiou L, Koutmos S, Tsiavos V, Roussaki P, Zilos A, Ragkou D, Kaltsas G, Piaditis G (2012) Pattern of adrenal morphology and function in patients with acromegaly. Eur J Clin Invest 42:275–281.  https://doi.org/10.1111/j.1365-2362.2011.02580.x CrossRefPubMedGoogle Scholar
  16. 16.
    Scaroni C, Selice R, Benedini S, De Menis E, Arosio M, Ronchi C, Gasperi M, Manetti L, Arnaldi G, Polenta B, Boscaro M, Albiger N, Martino E, Mantero F (2008) Adrenal morpho-functional alterations in patients with acromegaly. J Endocrinol Invest 31:602–606.  https://doi.org/10.1007/BF03345609 CrossRefPubMedGoogle Scholar
  17. 17.
    Ciresi A, Amato MC, Vetro C, Lo Coco R, Galluzzo A, Giordano C (2009) Adrenal morphology and function in acromegalic patients in relation to disease activity. Endocrine 36:346–354.  https://doi.org/10.1007/s12020-009-9230-y CrossRefPubMedGoogle Scholar
  18. 18.
    Ceccato F, Occhi G, Albiger NM, Rizzati S, Ferasin S, Trivellin G, Mantero F, Scaroni C (2011) Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. J Endocrinol Invest 34:353–360.  https://doi.org/10.1007/BF03347459 CrossRefPubMedGoogle Scholar
  19. 19.
    Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM (2016) Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 175:G1–G34.  https://doi.org/10.1530/EJE-16-0467 CrossRefPubMedGoogle Scholar
  20. 20.
    Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 23:57–63CrossRefPubMedGoogle Scholar
  21. 21.
    Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627–5631.  https://doi.org/10.1210/jc.2005-0531 CrossRefPubMedGoogle Scholar
  22. 22.
    Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F, Gaia E, Martino E, Lombardi G, Angeli A, Colao A (2005) Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 90:84–90.  https://doi.org/10.1210/jc.2004-0240 CrossRefPubMedGoogle Scholar
  23. 23.
    Colao A (2008) The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 69:347–358.  https://doi.org/10.1111/j.1365-2265.2008.03292.x CrossRefGoogle Scholar
  24. 24.
    Derwahl M, Broecker M, Kraiem Z (1999) Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 84:829–834.  https://doi.org/10.1210/jcem.84.3.5519 PubMedGoogle Scholar
  25. 25.
    Ruchala M, Skiba A, Gurgul E, Uruski P, Wasko R, Sowinski J (2009) The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuro Endocrinol Lett 30:382–386PubMedGoogle Scholar
  26. 26.
    Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marinò V, Di Sarno A, Merola B, Lombardi G (1998) Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 83:775–779CrossRefPubMedGoogle Scholar
  27. 27.
    Manetti L, Bogazzi F, Brogioni S, Grasso L, Lupi I, Genovesi M, Cecconi E, Gasperi M, Martino E (2002) Submandibular salivary gland volume is increased in patients with acromegaly. Clin Endocrinol (Oxf) 57:97–100CrossRefGoogle Scholar
  28. 28.
    Cohen O, Schindel B, Homburg R (1998) Uterine leiomyomata–a feature of acromegaly. Hum Reprod 13:1945–1946CrossRefPubMedGoogle Scholar
  29. 29.
    Reincke M, Fasnachat M, Vath S, Mora P, Allolio B (1996) Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22:757–761CrossRefPubMedGoogle Scholar
  30. 30.
    Shigematsu K, Niwa M, Kurihara M, Yamashita K, Kawai K, Tsuchiyama H (1989) Receptor autoradiographic localization of insulin-like growth factor-I (IGF-I) binding sites in human fetal and adult adrenal glands. Life Sci 45:383–389CrossRefPubMedGoogle Scholar
  31. 31.
    Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B (2002) Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 147:489–494CrossRefPubMedGoogle Scholar
  32. 32.
    Tsagarakis S, Kokkoris P, Roboti C, Malagari C, Kaskarelis J, Vlassopoulou V, Alevizaki C, Thalassinos N (1998) The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 48:627–633CrossRefGoogle Scholar
  33. 33.
    Chiodini I (2011) Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236.  https://doi.org/10.1210/jc.2010-2722 CrossRefPubMedGoogle Scholar
  34. 34.
    Perogamvros I, Vassiliadi DA, Karapanou O, Botoula E, Tzanela M, Tsagarakis S (2015) Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas. Eur J Endocrinol 173:719–725.  https://doi.org/10.1530/eje-15-0566 CrossRefPubMedGoogle Scholar
  35. 35.
    Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi A, Della Casa S (2011) The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf) 74(3):300–305.  https://doi.org/10.1111/j.1365-2265.2010.03928.x CrossRefGoogle Scholar
  36. 36.
    Kamio T, Shigematsu K, Kawai K, Tsuchiyama H (1991) Immunoreactivity and receptor expression of insulin like growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138:83–91PubMedPubMedCentralGoogle Scholar
  37. 37.
    Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE (1990) Effects of human growth hormone in men over 60 years old. N Eng J Med 323:1–6.  https://doi.org/10.1056/NEJM199007053230101 CrossRefGoogle Scholar
  38. 38.
    Yamamoto H, Kato Y (1993) Relationship between plasma insulin-like growth factor I (IGF-I) levels and body mass index (BMI) in adults. Endocr J 40:41–45CrossRefPubMedGoogle Scholar
  39. 39.
    Schneider HJ, Saller B, Klotsche J, März W, Erwa W, Wittchen HU, Stalla GK (2006) Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154:699–706.  https://doi.org/10.1530/eje.1.02131 CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2018

Authors and Affiliations

  1. 1.Department of Endocrinology and Metabolism, Faculty of MedicineOndokuz Mayis UniversitySamsunTurkey
  2. 2.Endocrinology and MetabolismLiv Hospitalİlkadım/SamsunTurkey

Personalised recommendations